Galectin Therapeutics (NASDAQ:GALT)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a report released on Thursday. They presently have a $10.00 target price on the stock, up from their prior target price of $6.00.

GALT has been the topic of several other research reports. ValuEngine raised Galectin Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Thursday, September 28th. Seaport Global Securities reiterated a “buy” rating and set a $5.00 price objective on shares of Galectin Therapeutics in a research note on Friday, October 6th. Roth Capital began coverage on Galectin Therapeutics in a research note on Thursday, October 19th. They issued a “buy” rating and a $8.00 price target for the company. Finally, Zacks Investment Research upgraded Galectin Therapeutics from a “hold” rating to a “buy” rating and set a $2.75 price objective on the stock in a report on Thursday, November 30th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $5.55.

Galectin Therapeutics (NASDAQ GALT) opened at $1.54 on Thursday. Galectin Therapeutics has a one year low of $0.87 and a one year high of $3.68.

Galectin Therapeutics (NASDAQ:GALT) last issued its quarterly earnings results on Tuesday, November 7th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.02. sell-side analysts expect that Galectin Therapeutics will post -0.52 EPS for the current year.

Several hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its position in shares of Galectin Therapeutics by 18.2% during the 2nd quarter. Vanguard Group Inc. now owns 871,510 shares of the company’s stock valued at $2,144,000 after buying an additional 134,165 shares during the period. Advisor Group Inc. raised its position in Galectin Therapeutics by 7.4% in the third quarter. Advisor Group Inc. now owns 519,850 shares of the company’s stock valued at $1,112,000 after purchasing an additional 35,850 shares during the period. Virtu KCG Holdings LLC raised its position in Galectin Therapeutics by 24.4% in the second quarter. Virtu KCG Holdings LLC now owns 107,203 shares of the company’s stock valued at $264,000 after purchasing an additional 21,008 shares during the period. Finally, Northern Trust Corp raised its position in Galectin Therapeutics by 4.4% in the second quarter. Northern Trust Corp now owns 75,097 shares of the company’s stock valued at $185,000 after purchasing an additional 3,176 shares during the period. 11.07% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “Galectin Therapeutics (GALT) Receives “Buy” Rating from HC Wainwright” was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this piece of content can be read at https://www.americanbankingnews.com/2017/12/07/galectin-therapeutics-galt-receives-buy-rating-from-hc-wainwright.html.

About Galectin Therapeutics

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions.

Receive News & Ratings for Galectin Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.